Asgard Alcobev Ltd
512025Asgard Alcobev Ltd's stock has fallen further than its earnings. EPS fell 25.0% in a year while the price moved −29.6%.
The sharpest disagreement: the engine is strong, but at the 85th percentile of its own range you are paying full price for it.
The price is in a downtrend (55 weeks in) while the P/E sits at the 85th percentile of its own 1-year range. Underneath, the last four quarters read improving — profit +290.8% year on year, and 67% of the last 2 years' profit arrived as cash. What settles it: whether the earnings grow into the multiple.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Asgard Alcobev Ltd trades at ₹34.4, in a downtrend and 55 weeks into that stage. That is −12.1% against its own 200-day average. It sits at 15% of a 52-week range of ₹30 to ₹57. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a downtrend — week 55 of stage 4, confirmed. At ₹34.4 it trades −12.1% versus its 200-day average and sits at 15% of its 52-week range (₹30–₹57).
Against the market, two honest reads. Cumulative: over the last 3.8 years the stock moved +310% while the NIFTY 500 moved +46% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Asgard Alcobev Ltd trades at 416.0× P/E, at the pricey end of its own range (85th percentile). Its long-run median P/E is 275.3×, measured across 1.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 416.0× is at the pricey end of its own range (85th percentile), against a long-run median of 275.3× measured over 1.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −25.0% against a −29.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Asgard Alcobev Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 6 quarters across 0 curves, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +74.1% | — | — | — |
| Profit | −50.0% | — | — | — |
| EPS | −25.0% | — | — | — |
| Share price | −29.6% | — | — | — |
4-Factor Sector Score
41.7/100 — rank 12 of 15 in Alcoholic Beverages · 69% evidence confidence
Asgard Alcobev Ltd scores 41.7 out of 100 against the 15 companies it is compared with in Alcoholic Beverages, ranking 12. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 20.4 + 5.3 + 8.5 + 7.5 = 41.7. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Asgard Alcobev Ltd reported ₹53.0 Cr of revenue in the Jun 26 quarter, +150.7% year on year. That is the 2nd straight quarter of year-on-year growth. The last full year, FY26, came in at ₹101 Cr. The last four reported quarters add to ₹133 Cr.
FY26 revenue came in at ₹101 Cr (+74.1% on the year). The latest quarter (Jun 26) printed ₹53.0 Cr, +150.7% year on year — the 2nd consecutive quarter of year-over-year growth.
Acceleration check: trailing-twelve-month revenue grew +68.3% over the last 4 quarters against +1,974.3%/yr over the last 8 — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Asgard Alcobev Ltd's operating margin is 9.7% in the Jun 26 quarter, +2.3 percentage points against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −5.0% to 8.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 9.7%, +2.3 pp against the same quarter a year ago. Across 3 fiscal years the operating margin has ranged −5.0%–8.0%.
Why the margin moved: operating margin went +2.3 pp year on year while gross margin went +44.7 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Asgard Alcobev Ltd earned ₹2.5 Cr of net profit in the Jun 26 quarter, +290.8% year on year. Full-year FY26 profit was ₹1.0 Cr. That is 4.8% of the quarter's revenue. The same quarter a year earlier earned ₹0.7 Cr. 2 of the last 12 reported quarters were loss-making.
Jun 26 profit was ₹2.5 Cr, +290.8% year on year. On the full year, FY26 printed ₹1.0 Cr (−50.0%).
Why profit moved: revenue contributed +150.7% and the margin +2.3 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +47.7% vs revenue +66.7%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 2 fiscal years 67% of Asgard Alcobev Ltd's reported profit arrived as operating cash — most of the profit is real cash. In FY26 that was ₹4.0 Cr of operating cash against ₹1.0 Cr of profit. After ₹76.0 Cr of capital spending, ₹−72.0 Cr was left as free cash.
FY26: operating cash of ₹4.0 Cr against reported profit of ₹1.0 Cr, leaving free cash of ₹−72.0 Cr after ₹76.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is 67% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 67%: the cash cycle tightened 133 days between FY24 and FY26 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: the bigger cash user is investment — capital spending ran 31.3× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Asgard Alcobev Ltd's cash conversion cycle runs 35 days in FY26, down from 168 days in FY24. Capital spending ran ₹94.0 Cr over the last 2 years. At FY26 sales of ₹101 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹10.0 Cr sits inside the business at any moment.
FY26: debtors at 126 days, inventory at 116 days — roughly 3.8 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 35 days, tighter than FY24's 168.
The full loop: cash goes out to suppliers and production on day 0; stock waits 116 days to sell; customers pay about 126 days after that; and suppliers themselves are paid at 207 days — netting out to the 35-day cycle.
In money terms: at FY26 sales of ₹101 Cr, each day of the cycle holds about ₹0.3 Cr — so the 35-day loop keeps roughly ₹10.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹94.0 Cr over the last 2 fiscal years against ₹3.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹0.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Asgard Alcobev Ltd earns a ROCE of 7% in FY26. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 1.0% net margin on 0.50× asset turns.
FY26 ROCE is 7%.
Why the return is what it is — the wiring (FY26): 1.0% net margin × 0.50× asset turns × 4.49× balance-sheet leverage ≈ 2.2% on equity. Margin does its share; leverage is a meaningful part of the equation.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Asgard Alcobev Ltd carries ₹73.0 Cr of borrowings against ₹45.0 Cr of equity in FY26, a debt-to-equity of 1.62. Operating profit covers the interest bill 4×. Over 2 years borrowings went from ₹0.0 Cr to ₹73.0 Cr. Capital spending ran ₹94.0 Cr across the last 2 of those years.
FY26: borrowings of ₹73.0 Cr against equity of ₹45.0 Cr — a debt-to-equity of 1.62. Operating profit covers the interest bill 4×. Over 2 years borrowings went from ₹0.0 Cr to ₹73.0 Cr while capital spending ran ₹94.0 Cr in just the last 2 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters added 59.8 points of Asgard Alcobev Ltd over 8 quarters, the biggest move on the register. That takes promoters to 60.0% of the company. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +59.8 points over 8 quarters to 60.0%.
Why the register moved: promoters drove it (+59.8 points) — steady accumulation by institutions reading the same numbers this page reads.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Asgard Alcobev Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Radico Khaitan LtdRADICO | 77.8/100Favorable setup100% evidence | LEADER | 30.8/35 Revenue 19.3% · PAT 76.4% · OPM change 6 pp 100% evidence | 21.1/25 ROCE 24.2% · OPM 21% 100% evidence | 7.9/20 P/E 85.9× · PEG 1.91 100% evidence | 18.0/20 RS sector 35.4% · RS bench 35.9% · 1Y 49.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 21.1 + 7.9 + 18 = 77.8 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Piccadily Agro Industries LtdPICCADIL | 65.5/100Favorable setup87% evidence | BREAKING OUT | 24.2/35 Revenue 28.5% · PAT 30.6% · OPM change -1 pp 100% evidence | 15.7/25 ROCE 18% · OPM 17% 100% evidence | 12.3/20 P/E 43× · PEG 1.38 65% evidence | 13.3/20 RS sector 3.6% · RS bench 2.4% · 1Y -15.3%9 of 11 weeks ahead 70% evidence |
| Exact sum: 24.2 + 15.7 + 12.3 + 13.3 = 65.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3G M Breweries LtdGMBREW | 64.8/100Mixed-positive evidence80% evidence | TURNING | 28.0/35 Revenue 21.3% · PAT 30% · OPM change 4 pp 95% evidence | 16.1/25 ROCE 18% · OPM 23% 95% evidence | 10.8/20 P/E 16.2× · PEG — 15% evidence | 9.9/20 RS sector 1.5% · RS bench 1.5% · 1Y 36.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 28 + 16.1 + 10.8 + 9.9 = 64.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4IFB Agro Industries LtdIFBAGRO | 57.2/100Mixed-positive evidence74% evidence | ASLEEP | 27.4/35 Revenue 38.9% · PAT 90.3% · OPM change 1 pp 95% evidence | 12.1/25 ROCE 12.7% · OPM 8% 95% evidence | 11.3/20 P/E 13.5× · PEG — 15% evidence | 6.4/20 RS sector -8% · RS bench -16.1% · 1Y 9.2%3 of 11 weeks ahead 70% evidence |
| Exact sum: 27.4 + 12.1 + 11.3 + 6.4 = 57.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8% and the one-year return is 9.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 5United Spirits LtdUNITDSPR | 56.3/100Mixed-positive evidence100% evidence | LEADER | 15.2/35 Revenue 3.1% · PAT 24.4% · OPM change -5 pp 100% evidence | 19.4/25 ROCE 26.4% · OPM 16% 100% evidence | 8.3/20 P/E 55.5× · PEG 3.12 100% evidence | 13.4/20 RS sector 5.6% · RS bench 5.8% · 1Y 7.2%10 of 12 weeks ahead 100% evidence |
| Exact sum: 15.2 + 19.4 + 8.3 + 13.4 = 56.3 · Decision use: Price leads the evidence: RS versus the benchmark is 5.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 6Globus Spirits LtdGLOBUSSPR | 53.7/100Mixed-positive evidence83% evidence | ASLEEP | 27.2/35 Revenue 7.9% · PAT 100% · OPM change 2 pp 100% evidence | 9.5/25 ROCE 11.2% · OPM 10% 100% evidence | 10.6/20 P/E 25.7× · PEG — 15% evidence | 6.4/20 RS sector -10.4% · RS bench -10.6% · 1Y -22.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 9.5 + 10.6 + 6.4 = 53.7 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -10.4% and the one-year return is -22.6%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7India Glycols LtdINDIAGLYCO | 53.6/100Mixed-positive evidence100% evidence | BASING | 20.9/35 Revenue 12% · PAT 29.9% · OPM change 1 pp 100% evidence | 13.7/25 ROCE 12.4% · OPM 15% 100% evidence | 14.0/20 P/E 6.3× · PEG 0.16 100% evidence | 5.0/20 RS sector -61.2% · RS bench 46.2% · 1Y -64.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.9 + 13.7 + 14 + 5 = 53.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Allied Blenders & Distillers LtdABDL | 51.1/100Mixed-positive evidence93% evidence | TURNING | 14.1/35 Revenue 8% · PAT -12.5% · OPM change 0 pp 100% evidence | 14.9/25 ROCE 18.4% · OPM 12% 100% evidence | 4.0/20 P/E 90.7× · PEG 4.13 65% evidence | 18.1/20 RS sector 28.2% · RS bench 28.1% · 1Y 30.1%7 of 12 weeks ahead 100% evidence |
| Exact sum: 14.1 + 14.9 + 4 + 18.1 = 51.1 · Decision use: Price leads the evidence: RS versus the benchmark is 28.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Tilaknagar Industries LtdTI | 47.6/100Mixed-negative evidence85% evidence | BREAKING OUT | 9.4/35 Revenue 100% · PAT -80% · OPM change -7 pp 100% evidence | 11.9/25 ROCE 11.8% · OPM 16% 80% evidence | 7.8/20 P/E 62.5× · PEG — 50% evidence | 18.5/20 RS sector 27.4% · RS bench 27.5% · 1Y 26.6%7 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 11.9 + 7.8 + 18.5 = 47.6 · Decision use: Price leads the evidence: RS versus the benchmark is 27.5%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Jagatjit Industries LtdJAGAJITIND | 42.4/100Mixed-negative evidence61% evidence | BREAKING OUT | 20.6/35 Revenue -29.9% · PAT 100% · OPM change 7.4 pp 71% evidence | 5.3/25 ROCE 10.5% · OPM 0.4% 76% evidence | 9.7/20 P/E 58.5× · PEG — 15% evidence | 6.8/20 RS sector -15.9% · RS bench 0.5% · 1Y -35.1%8 of 12 weeks ahead 70% evidence |
| Exact sum: 20.6 + 5.3 + 9.7 + 6.8 = 42.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Associated Alcohols & Breweries LtdASALCBR | 41.7/100Mixed-negative evidence81% evidence | ASLEEP | 8.6/35 Revenue -5.3% · PAT -4.6% · OPM change -3 pp 95% evidence | 14.6/25 ROCE 18% · OPM 11% 95% evidence | 14.4/20 P/E 15.7× · PEG — 50% evidence | 4.1/20 RS sector -21.3% · RS bench -22.7% · 1Y -36.1%0 of 11 weeks ahead 70% evidence |
| Exact sum: 8.6 + 14.6 + 14.4 + 4.1 = 41.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12Asgard Alcobev Ltdthis page512025 | 41.7/100Mixed-negative evidence69% evidence | TURNING | 20.4/35 Revenue 68.3% · PAT 33.1% · OPM change 2.3 pp 95% evidence | 5.3/25 ROCE 7.4% · OPM 9.7% 76% evidence | 8.5/20 P/E 416× · PEG — 15% evidence | 7.5/20 RS sector -3.4% · RS bench -15.3% · 1Y -27.9%1 of 11 weeks ahead 70% evidence |
| Exact sum: 20.4 + 5.3 + 8.5 + 7.5 = 41.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Sula Vineyards LtdSULA | 33.2/100Adverse evidence81% evidence | BASING | 7.9/35 Revenue -1.6% · PAT -56.9% · OPM change -2 pp 95% evidence | 11.2/25 ROCE 7.5% · OPM 14.7% 95% evidence | 10.7/20 P/E 44× · PEG — 50% evidence | 3.4/20 RS sector -29.8% · RS bench -24.2% · 1Y -52.6%0 of 11 weeks ahead 70% evidence |
| Exact sum: 7.9 + 11.2 + 10.7 + 3.4 = 33.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14United Breweries LtdUBL | 31.8/100Adverse evidence83% evidence | ASLEEP | 8.5/35 Revenue 1.5% · PAT -12.8% · OPM change -2 pp 100% evidence | 8.9/25 ROCE 10.7% · OPM 9% 100% evidence | 8.7/20 P/E 95.7× · PEG — 15% evidence | 5.7/20 RS sector -15% · RS bench -15.2% · 1Y -30.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 8.5 + 8.9 + 8.7 + 5.7 = 31.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Som Distilleries & Breweries LtdSDBL | 22.2/100Adverse evidence84% evidence | TURNING | 3.5/35 Revenue -33.5% · PAT -80% · OPM change -7.7 pp 95% evidence | 3.3/25 ROCE 5.7% · OPM 5.6% 95% evidence | 6.6/20 P/E — · PEG — 35% evidence | 8.8/20 RS sector -14.3% · RS bench -14.9% · 1Y -45%1 of 12 weeks ahead 100% evidence |
| Exact sum: 3.5 + 3.3 + 6.6 + 8.8 = 22.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Asgard Alcobev Ltd's share price today?
Asgard Alcobev Ltd trades at ₹34.4, −29.6% over the past year. The company is valued at ₹1,058 Cr. The stock sits at 15% of its 52-week range of ₹30–₹57, −12.1% versus its 200-day average. On the tape, the price is in a downtrend, 55 weeks in. — as of 28 September 2026.
What were Asgard Alcobev Ltd's latest quarterly results?
Asgard Alcobev Ltd reported revenue of ₹53.0 Cr and net profit of ₹2.5 Cr for the Jun 26 quarter. Revenue rose 150.7% and profit rose 290.8% year on year. Earnings per share were ₹0.06. The operating margin was 9.7%, 2.3 pp higher than a year earlier. — as of 28 September 2026.
What is Asgard Alcobev Ltd's revenue?
Asgard Alcobev Ltd reported revenue of ₹53.0 Cr in the Jun 26 quarter, +150.7% year on year. For the full FY26 fiscal year, revenue was ₹101 Cr (+74.1%). — as of 28 September 2026.
What is Asgard Alcobev Ltd's profit?
Asgard Alcobev Ltd earned ₹2.5 Cr of net profit in the Jun 26 quarter, +290.8% year on year. Full-year FY26 profit was ₹1.0 Cr. The operating margin ran 9.7% in the latest quarter. — as of 28 September 2026.
What is Asgard Alcobev Ltd's market cap?
Asgard Alcobev Ltd's market capitalisation is ₹1,058 Cr at a share price of ₹34.4. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 28 September 2026.
What is Asgard Alcobev Ltd's P/E ratio?
Asgard Alcobev Ltd trades at a P/E of 416.0×, at the 85th percentile of its own 1-year range, against a long-run median of 275.3×. This is a comparison with the stock's own history, not a value call — as of 28 September 2026.
Does Asgard Alcobev Ltd pay a dividend?
No — Asgard Alcobev Ltd has recorded a dividend payout of 0% of profit in each of its last 3 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 28 September 2026.
Is Asgard Alcobev Ltd overvalued?
On its own history, Asgard Alcobev Ltd looks expensive: its P/E of 416.0× sits at the 85th percentile of its 1-year range (long-run median 275.3×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 28 September 2026.
Is Asgard Alcobev Ltd growing?
Yes — Asgard Alcobev Ltd is growing: latest-quarter revenue +150.7% year on year, profit +290.8%, and the margin +2.3 pp at 9.7%. The earnings engine currently reads: improving — as of 28 September 2026.
How is Asgard Alcobev Ltd performing?
Asgard Alcobev Ltd is in a downtrend, 55 weeks in. Its latest quarter's revenue rose 150.7% and profit rose 290.8% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 28 September 2026.
Is Asgard Alcobev Ltd in an uptrend?
No — the price is in a downtrend (week 55 of stage 4), trading −12.1% versus its 200-day average and at 15% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 28 September 2026.
Is Asgard Alcobev Ltd beating the market?
On recent form, yes — Asgard Alcobev Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.8 years the stock moved +310% against the NIFTY 500's +46% — ahead of the index over the full window. — as of 28 September 2026.
Will Asgard Alcobev Ltd's share price go up?
This page publishes no price forecast for Asgard Alcobev Ltd. What it measures instead: the share price is ₹34.4, the price is in a downtrend 55 weeks in. Its P/E of 416.0× sits at the 85th percentile of its own 1-year range. — as of 28 September 2026.
Who owns Asgard Alcobev Ltd?
Promoters hold 60.0% of Asgard Alcobev Ltd, foreign institutions null%, domestic institutions null% and the public 40.0% (latest quarter). The biggest move on the register over the last two years: Promoters added 59.8 points over 8 quarters. — as of 28 September 2026.
Does Asgard Alcobev Ltd have too much debt?
It carries real leverage — Asgard Alcobev Ltd's debt-to-equity is 1.62, and operating profit covers the interest bill 4×. FY26 borrowings were ₹73.0 Cr against equity of ₹45.0 Cr. Read the returns on this page with that leverage in mind — as of 28 September 2026.
What is Asgard Alcobev Ltd's capex?
Asgard Alcobev Ltd spent ₹94.0 Cr on capital expenditure over the last 2 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹76.0 Cr, with ₹0.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 28 September 2026.
What is Asgard Alcobev Ltd's cash flow?
Asgard Alcobev Ltd generated ₹4.0 Cr of operating cash flow in FY26 and ₹−72.0 Cr of free cash flow after ₹76.0 Cr of capital spending. Reported profit that year was ₹1.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 28 September 2026.
Is Asgard Alcobev Ltd's profit real cash?
Mostly — over the last 2 fiscal years, 67% of Asgard Alcobev Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹4.0 Cr against reported profit of ₹1.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 28 September 2026.
Where is Asgard Alcobev Ltd in its business cycle?
Asgard Alcobev Ltd's FY26 operating margin was 7.0%, against a 3-year band of −5.0%–8.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 9.7%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 28 September 2026.
What could break the Asgard Alcobev Ltd story?
The sharpest disagreement: the engine is strong, but at the 85th percentile of its own range you are paying full price for it. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 28 September 2026.
Is Asgard Alcobev Ltd a stock worth studying right now?
This is not investment advice. The machine read: Asgard Alcobev Ltd's stock has fallen further than its earnings. EPS fell 25.0% in a year while the price moved −29.6%. The sharpest open question: whether the earnings grow into the multiple. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 28 September 2026.
Not SEBI Registered !! Not Investment advice !!